Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3359609 plus pembrolizumab vs pembrolizumab plus placebo in recurrent/metastatic head and neck squamous cell carcinoma
CTR20201147Phase 3Terminated
- Sponsor
- GSK
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of feladilimab in head and neck squamous cell carcinoma (HNSCC), sponsored by GSK. Started Oct 2020; status: terminated.
02
Drugs
feladilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20201147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201147.